
Twenty-six patients with advanced cancer received monthly intramuscular zzso zzso A zzso zzso zzso 12 X zzso zzso daily X 5 with escalating doses of zzso 25 to 40 zzso on day zzso As anticipated, zzso zzso were an zzso syndrome and zzso A clinically meaningful and dramatic partial response of zzso zzso persisted for zzso months associated with an zzso reduction from zzso to 299 zzso For Phase II zzso the authors recommend the above zzso 2A dose with zzso 40 zzso in patients with a performance score of 0 or 1 and no prior chemotherapy or significant radiation therapy which would enhance zzso 

